{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["64(12)"],"submitter":["Chen L"],"pubmed_abstract":["<sup>68</sup>Ga-labeled fibroblast activation protein inhibitor (<sup>68</sup>Ga-FAPI) PET/CT has demonstrated promising clinical results, with a higher SUV<sub>max</sub> and tumor-to-background ratio (TBR) in breast cancer (BC) patients than <sup>18</sup>F-FDG PET/CT. Here, we aimed to evaluate the suitability of <sup>68</sup>Ga-FAPI PET/CT for the early and late prediction of the pathologic response to neoadjuvant chemotherapy (NAC) in BC. <b>Methods:</b> Twenty-two consecutive patients with newly diagnosed BC and an indication for NAC were prospectively included. All patients underwent standard chemotherapy and <sup>68</sup>Ga-FAPI PET/CT at baseline, after 2 cycles of NAC (PET2), and 1 wk before surgery (PET3). SUV<sub>max</sub> was measured in the primary tumor region and positive reg"],"journal":["Journal of nuclear medicine : official publication, Society of Nuclear Medicine"],"pagination":["1899-1905"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10690122"],"repository":["biostudies-literature"],"pubmed_title":["<sup>68</sup>Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study."],"pmcid":["PMC10690122"],"pubmed_authors":["Wu K","Kong L","Zhu Y","Chen L","Zheng S","Xu S","Chen X","Miao W","Xue J"],"additional_accession":[]},"is_claimable":false,"name":"<sup>68</sup>Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study.","description":"<sup>68</sup>Ga-labeled fibroblast activation protein inhibitor (<sup>68</sup>Ga-FAPI) PET/CT has demonstrated promising clinical results, with a higher SUV<sub>max</sub> and tumor-to-background ratio (TBR) in breast cancer (BC) patients than <sup>18</sup>F-FDG PET/CT. Here, we aimed to evaluate the suitability of <sup>68</sup>Ga-FAPI PET/CT for the early and late prediction of the pathologic response to neoadjuvant chemotherapy (NAC) in BC. <b>Methods:</b> Twenty-two consecutive patients with newly diagnosed BC and an indication for NAC were prospectively included. All patients underwent standard chemotherapy and <sup>68</sup>Ga-FAPI PET/CT at baseline, after 2 cycles of NAC (PET2), and 1 wk before surgery (PET3). SUV<sub>max</sub> was measured in the primary tumor region and positive reg","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2025-04-25T17:37:01.869Z","creation":"2025-04-06T04:05:29.869Z"},"accession":"S-EPMC10690122","cross_references":{"pubmed":["37918866"],"doi":["10.2967/jnumed.123.266079"]}}